264 related articles for article (PubMed ID: 27126361)
1. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
[TBL] [Abstract][Full Text] [Related]
2. FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition.
Yu J; Zhang W; Gao F; Liu YX; Chen ZY; Cheng LY; Xie SF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2014 Apr; 13(2):184-91. PubMed ID: 24686546
[TBL] [Abstract][Full Text] [Related]
3. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Hu QD; Chen W; Yan TL; Ma T; Chen CL; Liang C; Zhang Q; Xia XF; Liu H; Zhi X; Zheng XX; Bai XL; Yu XZ; Liang TB
Cancer Lett; 2012 Dec; 325(2):207-13. PubMed ID: 22781398
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
Zhou M; Zhang XY; Yu X
Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-induced epithelial-mesenchymal transition through SEMA 4A in hepatocellular carcinoma.
Pan JX; Wang F; Ye LY
Biochem Biophys Res Commun; 2016 Oct; 479(4):610-614. PubMed ID: 27697528
[TBL] [Abstract][Full Text] [Related]
6. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma.
Tanaka S; Shiraha H; Nakanishi Y; Nishina S; Matsubara M; Horiguchi S; Takaoka N; Iwamuro M; Kataoka J; Kuwaki K; Hagihara H; Toshimori J; Ohnishi H; Takaki A; Nakamura S; Nouso K; Yagi T; Yamamoto K
Int J Cancer; 2012 Dec; 131(11):2537-46. PubMed ID: 22488108
[TBL] [Abstract][Full Text] [Related]
7. CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells.
Yang L; Chang Y; Cao P
Exp Cell Res; 2018 Oct; 371(1):231-237. PubMed ID: 30107147
[TBL] [Abstract][Full Text] [Related]
8. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.
Zhang Y; Wu W; Sun Q; Ye L; Zhou D; Wang W
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760121
[TBL] [Abstract][Full Text] [Related]
9. Effects of UPF1 expression on EMT process by targeting E‑cadherin, N‑cadherin, Vimentin and Twist in a hepatocellular carcinoma cell line.
Li Y; Zhang T; Qin S; Wang R; Li Y; Zhou Z; Chen Y; Wu Q; Su F
Mol Med Rep; 2019 Mar; 19(3):2137-2143. PubMed ID: 30628676
[TBL] [Abstract][Full Text] [Related]
10. LINC00922 promotes the proliferation, migration, invasion and EMT process of liver cancer cells by regulating miR-424-5p/ARK5.
Ye Z; He Q; Wang Q; Lin Y; Cen K; Chen X
Mol Cell Biochem; 2021 Oct; 476(10):3757-3769. PubMed ID: 34097192
[TBL] [Abstract][Full Text] [Related]
11. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
[TBL] [Abstract][Full Text] [Related]
12. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1.
Zhao XL; Sun T; Che N; Sun D; Zhao N; Dong XY; Gu Q; Yao Z; Sun BC
J Cell Mol Med; 2011 Mar; 15(3):691-700. PubMed ID: 20219012
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells via inducing Twist1 expression.
Zhang XD; Dong XQ; Xu JL; Chen SC; Sun Z
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(13):3061-3068. PubMed ID: 28742200
[TBL] [Abstract][Full Text] [Related]
14. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
[TBL] [Abstract][Full Text] [Related]
15. RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition.
Song FN; Duan M; Liu LZ; Wang ZC; Shi JY; Yang LX; Zhou J; Fan J; Gao Q; Wang XY
PLoS One; 2014; 9(9):e108507. PubMed ID: 25268581
[TBL] [Abstract][Full Text] [Related]
16. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
17. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
18. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
19. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
Yu M; Han G; Qi B; Wu X
Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
[TBL] [Abstract][Full Text] [Related]
20. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
Zhang C; Guo F; Xu G; Ma J; Shao F
Oncol Rep; 2015 Apr; 33(4):1872-82. PubMed ID: 25653024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
